Arcutis Biotherapeutics, Inc. ARQT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.4M-18.6% | $129.5M+30.5% | $99.22M+21.7% | $81.5M+23.8% | $65.85M-7.7% | ||
| $9.78M-16.3% | $11.69M+34.6% | $8.69M+15.9% | $7.49M-15.2% | $8.83M+27.9% | ||
| $95.61M-18.8% | $117.82M+30.1% | $90.53M+22.3% | $74.01M+29.8% | $57.02M-11.5% | ||
| 90.7%-0.3pp | 91%-0.3pp | 91.2%+0.4pp | 90.8%+4.2pp | 86.6%-3.7pp | ||
| $30.63M+49.8% | $20.45M+4.3% | $19.6M+0.8% | $19.45M+10.9% | $17.54M+21.2% | ||
| $74.08M-6.2% | $78.98M+26.6% | $62.4M-9.8% | $69.17M+8.1% | $64M+11.1% | ||
| $114.49M+3.0% | $111.12M+22.5% | $90.69M-5.6% | $96.12M+6.4% | $90.38M+14.4% | ||
| -$9.09M— | —— | $8.53M+158% | -$14.61M+40.4% | -$24.53M-221% | ||
| -8.6%— | —— | 8.6%+26.5pp | -17.9%+19.3pp | -37.3%-26.6pp | ||
| $4.37M+45.6% | $3M-2.3% | $3.07M+1.4% | $3.03M+1.6% | $2.98M-46.3% | ||
| -$20K— | —— | $2.04M-2.9% | $2.1M+986% | $193K— | ||
| $93K-80.2% | $470K+488% | $80K-76.6% | $342K+22.6% | $279K-13.6% | ||
| -$11.3M— | —— | $7.41M+147% | -$15.89M+36.6% | -$25.06M-132% | ||
| -10.7%— | —— | 7.5%+27.0pp | -19.5%+18.6pp | -38.1%-22.9pp | ||
| -$0.09— | —— | $0.06+146% | -$0.13+35.0% | -$0.20-150% | ||
| -$8.53M— | —— | $9.09M+165% | -$14.05M+34.3% | -$21.4M-198% | ||
| -8.1%— | —— | 9.2%+26.4pp | -17.2%+15.3pp | -32.5%-22.4pp | ||
| -$9.09M— | —— | $8.53M+158% | -$14.61M+40.4% | -$24.53M-221% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s revenue?
- Arcutis Biotherapeutics, Inc. (ARQT) generated $415.6M in revenue over the trailing twelve months, up 95.3% year over year.
- Is Arcutis Biotherapeutics, Inc. profitable?
- Arcutis Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $44.8M over the trailing twelve months, a -13.9% net margin.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
- What is Arcutis Biotherapeutics, Inc.'s earnings per share?
- Arcutis Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.36.
- Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
